share_log

NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones With Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases

NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones With Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases

neurobo pharmaceuticals宣布战略重组,将公司更名为MetaVia,以反映公司对心血管代谢疾病的关注,并迎接重要临床里程碑
PR Newswire ·  2024/11/18 21:01

New Nasdaq Ticker Symbol will be MTVA

纳斯达克的新逐笔明细标的将是MTVA

CAMBRIDGE, Mass., Nov. 18, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a strategic realignment, ahead of important clinical milestones, with a corporate name change to "MetaVia Inc.," which will be effective on November 29, 2024 (the "Effective Date"). In parallel, the Company's common stock will begin trading on the Nasdaq Stock Market under the new ticker symbol, "MTVA," which is expected to be operative as of the Effective Date. As part of its corporate name change, the company will also launch a new website, metaviatx.com, and a new company logo, on the Effective Date.

马萨诸塞州剑桥,2024年11月18日/PRNewswire/ - NeuroBo Pharmaceuticals, Inc. (纳斯达克: NRBO),一家临床阶段生物技术公司,专注于改善心脏代谢性疾病,今天宣布在重要临床里程碑之前进行战略重新调整,公司更名为"MetaVia Inc.",将于2024年11月29日("生效日")生效。 与此同时,公司的普通股将在纳斯达克股市以新的逐笔明细代码"MTVA"开始交易,预计将于生效日起生效。作为公司更名的一部分,公司还将在生效日推出新网站metaviatx.com和新公司标识。

The Company's CUSIP number and transfer agent will remain unchanged. Shareholders were not required to take any specific action with respect to the corporate name change or new ticker symbol. The corporate name change and new ticker symbol will not impact the Company's operations, management or structure.

公司的CUSIP编号和过户代理将保持不变。股东不需要采取任何具体行动来应对公司更名或新的逐笔明细标的。公司的更名和新的逐笔明细标的不会影响公司的运营、管理或结构。

"Our corporate name change to MetaVia, ahead of important clinical milestones, represents the final step in our transition to develop innovative therapies for the management of cardiometabolic diseases, since in-licensing our two next generation assets from our strategic partner, Dong-A ST Co., Ltd., targeting the obesity and metabolic dysfunction-associated steatohepatitis (MASH) markets," stated Hyung Heon Kim, President and Chief Executive Officer of NeuroBo. "We remain well-funded following our successful June financing of up to $70 million in aggregate gross proceeds, with $20 million upfront and $50 million of clinical milestone-based warrants.

神经波首席执行官金亨贤表示:"在重要临床里程碑之前,我们将公司更名为MetaVia,这代表着我们转型发展创新治疗心脏代谢性疾病的最后一步,自从从战略伙伴东亚圣公司处许可我们的两个下一代资产,主要针对肥胖和代谢紊乱相关的脂质肝炎(MASH)市场。" "在成功进行了截至总额为7000万美元的六月融资后,我们的资金状况良好,其中包括2000万美元的预付款和基于临床里程碑的5000万美元的认股权证。

"As previously announced, in December 2024, we expect to report data from the Phase 2a clinical trial evaluating the efficacy and safety of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist for the treatment of MASH. Additionally, in the first quarter of next year, we anticipate reporting top-line data from the planned cohorts from the multiple ascending dose (MAD) portion of our Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity. Based on the preclinical data generated to date, as well as DA-1726's balanced activation of GLP1R and glucagon receptors, which increases energy expenditure, we believe that DA-1726 may become a best-in-class obesity drug with a better tolerability profile than currently marketed GLP-1 agonists, and those now in late-stage clinical trials."

如先前宣布的,我们预期在2024年12月报告DA-1241的2a期临床试验数据,评估这种新型G蛋白耦联受体119(GPR119)激动剂用于治疗MASH的疗效和安全性。此外,明年第一季度,我们计划报道DA-1726的计划分级升剂量(MAD)部分的顶线数据,这是一种新型的双氧肽素(OXM)类似物激动剂,具有糖皮质激素样肽-1受体(GLP1R)和糖皮肽受体(GCGR)的功能,用于治疗肥胖。 根据迄今产生的临床前数据,以及DA-1726平衡激活GLP1R和糖皮肽受体,增加了能量消耗,我们相信DA-1726有可能成为一种拥有更好耐受性概况的最佳肥胖药物,优于目前市场上的GLP-1激动剂和目前处于后期临床试验阶段的药物。

About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control.

关于NeuroBo Pharmaceuticals
neurobo pharmaceuticals股份有限公司是一家专注于转化心脏代谢疾病的临床生物技术公司。该公司目前正在开发DA-1726用于肥胖治疗,正在开发DA-1241用于治疗代谢功能相关脂肪肝(MASH)。DA-1726是一种新型氧云调质激素(OXM)类似物,作为胰高血糖素样肽-1受体(GLP1R)和胰高血糖素受体(GCGR)双激动剂发挥作用。OXm是一种天然存在的肠道激素,能激活GLP1R和GCGR,从而减少食物摄入量并增加能量消耗,从而可能导致相对于选择性GLP1R激动剂更好的体重减轻。DA-1241是一种新型的G蛋白偶联受体119(GPR119)激动剂,能促进关键的肠道肽GLP-1,GIP和PYY的释放。在临床前研究中,DA-1241显示出对肝脏炎症,脂质代谢,体重减轻和葡萄糖代谢具有积极作用,减少肝脂变性,肝炎炎症和肝纤维化,同时改善葡萄糖控制。

For more information, please visit .

更多资讯,请访问。

Forward Looking Statements
Certain statements in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believes", "expects", "anticipates", "may", "will", "should", "seeks", "approximately", "potential", "intends", "projects", "plans", "estimates" or the negative of these words or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, without limitation, those risks associated with NeuroBo's ability to execute on its commercial strategy; the timeline for regulatory submissions; the ability to obtain regulatory approval through the development steps of NeuroBo's current and future product candidates; the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of NeuroBo; the cooperation of NeuroBo's contract manufacturers, clinical study partners and others involved in the development of NeuroBo's current and future product candidates; potential negative interactions between NeuroBo's product candidates and any other products with which they are combined for treatment; NeuroBo's ability to initiate and complete clinical trials on a timely basis; NeuroBo's ability to recruit subjects for its clinical trials; whether NeuroBo receives results from NeuroBo's clinical trials that are consistent with the results of pre-clinical and previous clinical trials; impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; the effects of changes in applicable laws or regulations; the effects of changes to NeuroBo's stock price on the terms of the license agreement and any future fundraising; and other risks and uncertainties described in NeuroBo's filings with the Securities and Exchange Commission, including NeuroBo's most recent Annual Report on Form 10-K. Forward-looking statements speak only as of the date when made. NeuroBo does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

前瞻性声明
本新闻稿中的某些声明可能被视为根据1995年《私人证券诉讼改革法案》的意义属前瞻性声明。诸如"相信"、"预计"、"期待"、"可能"、"将"、"应该"、"寻求"、"大约"、"潜在"、"意图"、"项目"、"计划"、"估计"等词或这些词的否定形式,或其他类似术语(以及其他涉及未来事件、状况或情况的词语或表达)旨在识别前瞻性声明。前瞻性声明预测、投影及其他关于基于当前期望和假设的未来事件的声明,并因此受到风险和不确定性的影响。许多因素可能导致实际未来事件与本新闻稿中前瞻性声明大不相同,包括但不限于与NeuroBo执行其商业策略的风险相关的那些风险;监管提交的时间表;通过NeuroBo当前和未来产品候选品的开发步骤获得监管批准的能力;实现与东亚制药的许可协议对NeuroBo未来的金融和运营结果的影响,包括NeuroBo与其代工厂商、临床研究合作伙伴和其他参与NeuroBo当前和未来产品候选品开发的人之间的合作;NeuroBo产品候选品与联合治疗的任何其他产品之间潜在负面交互的能力;NeuroBo及时启动和完成临床试验的能力;NeuroBo招募临床试验对象的能力;NeuroBo是否从临床试验中获得与前临床和先前临床试验结果一致的结果;与许可协议相关的已知和未知成本的影响,包括与许可协议有关的任何诉讼或监管行动的成本;适用法律或法规变化的影响;NeuroBo股价变化对许可协议条款和任何未来融资的影响;以及NeuroBo在提交给证券交易委员会的申报中描述的其他风险和不确定性,包括NeuroBo最近的年度报告10-k的。前瞻性声明仅在作出时有效。NeuroBo并不承担任何公开更新或修订前瞻性声明的义务,除非法律要求。

Contacts:

联系人:

NeuroBo Pharmaceuticals
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
[email protected]

NeuroBo Pharmaceuticals
Marshall H. Woodworth
首席财务官
+1-857-299-1033
[email protected]

Rx Communications Group
Michael Miller
+1-917-633-6086
[email protected]

Rx Communications Group
Michael Miller
+1-917-633-6086
[email protected]

SOURCE NeuroBo Pharmaceuticals, Inc.

来源:NeuroBo Pharmaceuticals,Inc。

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

想要您公司的新闻在PRNEWSWIRE.COM上特色呈现吗?

440k+
440k+

Newsrooms &
新闻发布室&

Influencers
影响力人士
9k+
9k+

Digital Media
数字媒体

Outlets
Outlets
270k+
270k+

Journalists
记者

Opted In
Opted In
GET STARTED
开始使用
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发